monocrotaline pyrrole

Known as: dehydromonocrotaline 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1972-2017
0246819722017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Pyrrolizidine alkaloids initiate disease in the lung (pulmonary hypertension), liver (veno-occlusive disease and cirrhosis), and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Primary pulmonary hypertension (PPH) is still a refractory disease, and patients deteriorate despite any treatment. We… (More)
Is this relevant?
2000
2000
A single administration of monocrotaline to rats results in pathologic alterations in the lung and heart similar to human… (More)
Is this relevant?
1998
1998
In the monocrotaline (MCT) model of pulmonary hypertension, the pulmonary vascular endothelium is the likely early target of the… (More)
Is this relevant?
1993
1993
Monocrotaline pyrrole (MCTP) is a putative, toxic metabolite of the pyrrolizidine alkaloid, monocrotaline (MCT). When given… (More)
Is this relevant?
1991
1991
Monocrotaline pyrrole (MCTP), a putative metabolite of the naturally occurring plant toxin, monocrotaline (MCT), causes lung… (More)
Is this relevant?
1990
1990
A single, intravenous administration of a low dose of monocrotaline pyrrole (MCTP), a derivative of the pyrrolizidine alkaloid… (More)
Is this relevant?
1984
1984
Monocrotaline pyrrole (MCTP) causes lung injury, pulmonary hypertension, and right ventricular hypertrophy in rats. To determine… (More)
Is this relevant?
1983
1983
Chemically synthesized monocrotaline pyrrole (MCTP) was administered to adult male rats at a dose of 5 mg/kg in the tail vein… (More)
Is this relevant?
1977
1977
Investigations were carried out to determine the lung lesions responsible for the development of pulmonary heart disease, cor… (More)
Is this relevant?